- Home
- YSXT vs INAB Comparison
YSXT vs INAB Comparison
Compare YSXT & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | INAB |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 22.9M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | YSXT | INAB |
|---|---|---|
| Price | $1.33 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $108.00 |
| AVG Volume (30 Days) | ★ 622.6K | 71.3K |
| Earning Date | 02-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.96 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $78,350,172.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.34 | ★ N/A |
| Revenue Growth | ★ 18.45 | N/A |
| 52 Week Low | $1.03 | $1.17 |
| 52 Week High | $9.96 | $12.53 |
Technical Indicators
Market Signals| Indicator | YSXT | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.96 | 43.48 |
| Support Level | $1.28 | $1.85 |
| Resistance Level | $1.39 | $2.07 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 71.59 | 12.00 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.